Randomized, multicenter, phase III trial of docetaxel plus epirubicin (ET) with or without capecitabine (X) as first-line therapy for stage IV breast cancer (BC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback